Page last updated: 2024-11-13

leu-ser-lys-leu peptide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID71312184
MeSH IDM0469280

Synonyms (14)

Synonym
leucyl-seryl-lysyl-leucyl peptide
leu-ser-lys-leu peptide
AC-31401
leu-ser-lys-leu-nh2, >=95% (hplc)
lskl, inhibitor of thrombospondin (tsp-1)
HY-P0299
tsp-1 inhibitor peptide lskl
h-leu-ser-lys-leu-nh2
283609-79-0
(2s)-6-amino-n-[(2s)-1-amino-4-methyl-1-oxopentan-2-yl]-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]hexanamide
MS-28396
PD078448
inhibitor of thrombospondin ;tsp-1
lskl

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Metalloproteases involved in extracellular matrix remodeling play a pivotal role in cell response by regulating the bioavailability of cytokines and growth factors."( In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1.
Bonnier, D; Laurent, MA; Moroy, G; Théret, N; Tufféry, P, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (18.75)29.6817
2010's11 (68.75)24.3611
2020's2 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]